Case Explanation: Prostate Carcinoma with Nodal Metastasis (Mr. Aribabu Dora, 71M)

This is a clinical case sheet from a Nephrology ward, documenting an elderly man admitted with a provisional diagnosis of prostate carcinoma with nodal metastasis, complicated by renal impairment and possible infection. Here's how the pieces fit together.

1. Patient Profile & Presentation

Mr. Aribabu Dora, 71M, Ht 158 cm, Wt 60 kg, BMI 24.3 (normal weight)
Admitted to Nephrology (General Ward) with scrotal pain and tiredness x 4 days
Notifiable disease: cancer; no significant family history

Why Nephrology, not Urology/Oncology? The admitting concern was likely his deranged renal function (see labs below), which commonly happens in advanced prostate cancer when pelvic/retroperitoneal nodal metastases compress the ureters, or when the tumor itself causes bladder outlet/ureteric obstruction — leading to obstructive uropathy and renal failure.

2. Examination Findings

Finding	Value	Interpretation
Lymphadenopathy	Yes	Consistent with nodal spread of prostate carcinoma
Pedal edema	Yes (bilateral)	Could reflect lymphatic/venous obstruction from pelvic nodal disease, hypoalbuminemia, fluid retention from renal impairment, or a mineralocorticoid effect of abiraterone (see below)
Temp	39.6°C	Fever — suggests superimposed infection (urosepsis, or infected scrotal swelling given the presenting complaint)
BP	100/70	Low-normal, non-hypertensive despite fever
SpO2	94%	Mildly reduced, non-critical
CVS/RS/Abdomen/CNS	Normal	No acute cardiopulmonary or neurological involvement

3. Laboratory Interpretation

Severe normocytic anemia: Hb 6.7 g/dL, MCV 81 (normal range), MCHC 33.5 — normocytic, consistent with anemia of chronic disease/malignancy and CKD (bone marrow involvement by metastatic disease and reduced erythropoietin from failing kidneys are both plausible contributors).

Leukocyte picture: WBC 10.72 x10³/µL with marked neutrophilia (85.8%, ANC 9200) and lymphopenia (8.2%, absolute count 0.88 x10³/µL) — classic pattern of acute bacterial infection/sepsis superimposed on malignancy-related immune suppression. This supports the fever and justifies empiric IV antibiotics.

Renal function — the dominant abnormality:

Urea 51.2 mg/dL, Creatinine 3.3 mg/dL, calculated creatinine clearance (CaCOD) 17.8 mL/min → this is Stage 4 CKD / severe renal impairment, almost certainly from ureteric obstruction by metastatic pelvic/retroperitoneal lymph nodes (a well-recognized complication of locally advanced/metastatic prostate cancer).
Bicarbonate 21.7 mEq/L (mild metabolic acidosis) — typical of CKD.
Hyponatremia (128) and hypokalemia (3.3) with an elevated urine spot sodium (60 mEq/L) point to renal salt-wasting rather than volume depletion, consistent with intrinsic renal (tubular) dysfunction.
RBS 126.8 mg/dL — mildly elevated, likely stress hyperglycemia in the setting of acute illness/fever.

Urinalysis: Low specific gravity (1.005) reflects impaired concentrating ability (again fitting CKD); mild pyuria (pus cells 3-5/HPF) and epithelial cells suggest low-grade urinary tract inflammation, but no significant hematuria or proteinuria.

4. Diagnosis

"From objective and subjective evidence, the patient was diagnosed with prostate carcinoma with nodal metastasis." The clinical picture (elderly male, lymphadenopathy, obstructive renal failure, anemia, fever/leukocytosis suggesting infection) is a coherent presentation of locally advanced/metastatic prostate cancer with a secondary infective/renal complication.

5. Treatment Analysis

Drug	Purpose
Inj Cefoperazone-Sulbactam → later Meropenem	Empiric, then escalated broad-spectrum IV antibiotics for presumed sepsis/infection (fever + neutrophilia)
Inj Pantoprazole	Gastric (stress ulcer) prophylaxis
Inj Ondansetron	Antiemetic
Tab Acetylcysteine + Taurine (Nacsave)	Antioxidant/renal-protective supplement, commonly used in CKD
Tab Sodium bicarbonate (Sodoal)	Corrects the metabolic acidosis of CKD
Tab Sodium chloride (Addna)	Corrects hyponatremia from renal salt wasting
Sachet Lamuro Nephro	Renal-specific amino acid/electrolyte supplement for CKD
Inj Tramadol	Analgesia for scrotal pain
Tab Abiraterone acetate 500 mg BID (2-0-0)	Definitive anticancer therapy - a CYP17 (17α-hydroxylase/C17,20-lyase) inhibitor that blocks androgen synthesis, used for metastatic prostate cancer

A pharmacological point worth flagging: abiraterone is conventionally co-administered with a low-dose corticosteroid (prednisone/prednisolone) because blocking CYP17 causes compensatory ACTH rise and mineralocorticoid excess (hypokalemia, fluid retention, hypertension). This patient's hypokalemia and bilateral pedal edema could be partly drug-related, and no corticosteroid is listed in this chart - something a treating clinician would typically want to address.

6. Drug and Food Interactions Noted in the Case

Ondansetron + Tramadol - ondansetron can blunt tramadol's analgesic effect (via 5-HT3 antagonism reducing the descending pain-modulation pathway tramadol partly relies on) while both raise serotonergic tone, increasing serotonin syndrome risk.
Abiraterone + Tramadol - abiraterone inhibits CYP2D6, which can raise tramadol (and its metabolite) levels, increasing toxicity risk.
Tramadol + alcohol - additive CNS depression.
Abiraterone + food - food (especially fatty meals) massively increases abiraterone absorption (up to 10x), which is why it must be taken on an empty stomach; taking it with food risks toxicity.

One additional renal-dosing consideration not explicitly in the notes: with a creatinine clearance of ~17.8 mL/min, meropenem and tramadol both need dose/interval adjustment (e.g., meropenem is typically reduced to 500 mg q12h rather than standard 1g dosing in this degree of renal impairment) to avoid drug accumulation and toxicity.

Summary

This is a 71-year-old man with metastatic prostate carcinoma (nodal spread) presenting with scrotal pain and fatigue, found to have severe anemia, obstructive-pattern renal failure (Stage 4 CKD, likely from nodal compression of the ureters), electrolyte derangements from renal salt wasting, and a superimposed bacterial infection. He was managed with broad-spectrum antibiotics, renal supportive therapy (bicarbonate, sodium, nephro-specific supplements), symptomatic care (analgesia, antiemetic), and abiraterone acetate as definitive hormonal therapy for the underlying cancer - with a few pharmacy-relevant gaps worth double-checking (missing corticosteroid co-therapy with abiraterone, and renal dose adjustment of meropenem/tramadol).

Why hb level is low

Finding Sources

The patient's Hb of 6.7 g/dL is severe anemia, and the red cell indices tell you what type: MCV 81 (normal, 80-100) and MCHC 33.5 (normal) = a normocytic, normochromic anemia — not iron deficiency (which would be microcytic) and not B12/folate deficiency (which would be macrocytic). This pattern points to a small set of causes, and in this patient several are stacked together:

1. Anemia of Chronic Kidney Disease (the dominant driver) His calculated creatinine clearance is only 17.8 mL/min (Stage 4 CKD, creatinine 3.3 mg/dL, urea 51.2 mg/dL). The kidneys' peritubular fibroblasts produce erythropoietin (EPO), the hormone that drives red cell production in the bone marrow. As kidney tissue is damaged, EPO production falls, and the marrow simply can't keep up red cell output — this is the classic "anemia of CKD," and it is normocytic/normochromic, exactly matching his indices.

2. Anemia of malignancy / chronic inflammation Metastatic cancer (here, prostate carcinoma with nodal spread) drives chronic inflammatory cytokine release (IL-6 etc.), which raises hepcidin. Hepcidin blocks iron release from macrophages and gut absorption, so iron gets "locked away" even though total body iron is fine — the marrow is iron-starved despite normal stores. This also produces a normocytic/normochromic anemia and commonly coexists with CKD anemia in cancer patients.

3. Possible bone marrow involvement Prostate cancer has a strong tendency to metastasize to bone, and marrow infiltration can blunt erythropoiesis directly (myelophthisic effect). His differential count already shows lymphopenia (absolute lymphocyte count 0.88 x10³/µL), which can be seen with marrow/immune stress in advanced malignancy — worth correlating with a bone scan/imaging if not already done.

4. Acute illness/sepsis contribution His fever (39.6°C) and neutrophilia suggest an active infection, and acute inflammatory states transiently suppress marrow erythropoiesis and shorten red cell survival, compounding the anemia during this admission.

What's less likely here: Active bleeding — urinalysis showed no significant hematuria (RBC 0-1/HPF, blood negative), so this doesn't look like a bleeding-related anemia.

Bottom line: This is a multifactorial normocytic anemia — anemia of CKD (low EPO) plus anemia of malignancy/inflammation (hepcidin-mediated iron sequestration), with possible bone marrow infiltration by metastatic disease and some contribution from acute infection. This is why such patients often need iron studies, EPO-stimulating agents (once infection is controlled and cancer-related contraindications assessed), and sometimes transfusion when Hb is this low (6.7 g/dL is a level where transfusion is frequently considered, especially with symptoms like his reported tiredness).

This is a shared conversation. Sign in to Orris to start your own chat.